6-amino-2-butylamino-9H-purine | 5463-09-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 6-amino-2-butylamino-9H-purine
• 英文别名: 2-N-butyl-7H-purine-2,6-diamine
• CAS: 5463-09-2
• 化学式: C₉H₁₄N₆
• 分子量: 206.25
• InChiKey: BYCJYBHYAVBYGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  92.5
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-amino-2-butylamino-9H-purine 在 sodium hydroxide 、 溴 、 potassium carbonate 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.0h， 生成 2-N-butyl-8-methoxy-9-[(4-phenylmethoxyphenyl)methyl]purine-2,6-diamine
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Novel 9-Substituted-8-Hydroxyadenine Derivatives as Potent Interferon Inducers

  摘要：

  Recently we reported the adenine derivatives 3a-d as novel interferon (IFN) inducers. In the present study, we conducted a detailed structure-activity relationship study of analogues of 3a-d with respect to their IFN-inducing activity, mainly focusing on the N(9)-position of the adenine. From this study, we found that introduction of the 3-pyridylmethyl moiety was effective to increase in vitro activity, and compound 9ae was identified as being the most potent IFN inducer. This compound gave a minimum effective concentration (MEC) of 3 nM, which is comparable with that of R-848, a second generation IFN inducer. Compound 9ae also demonstrated potent IFN-inducing activity at a dose of 0.1 mg/kg by oral administration in mice. Furthermore, compound 9ae induced IFN in monkeys in a dose dependent manner, with a potency superior to that of R-848. In addition, 9ae did not cause emesis in ferrets even at a dose of 30 mg/kg. In this study the maximum plasma concentration of 9ae was 1019 ng/mL (ca. 3.1 mu M), which was approximately 1000-fold higher than the MEC value. Therefore, with respect to both the efficacy and the safety margin, compound 9ae (SM-276001) is considered to be a promising compound as an orally active IFN inducer.

  DOI：

  10.1021/jm051089s
• 作为产物：
  描述：

  正丁胺 、 2-氯-6-氨基嘌呤 在 水 、 二氯甲烷 、 甲醇 作用下， 反应 150.0h， 以to give the captioned compound (2.08 g, yield 30%) as a yellowish的产率得到6-amino-2-butylamino-9H-purine
  参考文献：
  名称：

  NOVEL ADENINE COMPOUND AND USE THEREOF

  摘要：

  这是一种适用于局部给药的药物，可作为抗过敏剂使用。该药物含有一种腺嘌呤化合物作为活性成分，其通用式表示为（1）：[其中环A代表6至10个成员、单环或双环、芳香族碳氢化合物或5至10个成员、单环或双环、芳香族杂环，其中选自0至2个氮原子、0或1个氧原子和0或1个硫原子中的一到三个杂原子；n为0至2的整数；m为0至2的整数；R代表卤素、（未）取代烷基等；X1代表氧、硫、NR1（R1代表氢或烷基）或单键；Y1代表单键、亚烷基等；Y2代表单键、亚烷基等；Z代表亚烷基；Q1和Q2中至少一个代表—COOR10（其中R10代表（未）取代烷基等），等等]或该化合物的药学上可接受的盐。

  公开号：

  US20100256118A1

文献信息

• Modulators of toll-like receptor 7
  申请人：Chong S. Lee

  公开号：US20080008682A1

  公开（公告）日：2008-01-10

  The present application provides for a compound of Formula I or II: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active agent.

  本申请提供了一种公式I或II的化合物： 或其药用可接受的盐、溶剂化物和/或酯，包含此类化合物的组合物，包括施用此类化合物的治疗方法和包括与至少一个附加活性剂施用此类化合物的治疗方法。
• [EN] USE OF A TLR7 AGONIST FOR THE TREATMENT OF CANCER<br/>[FR] UTILISATION D'UN AGONISTE DE TLR7 POUR LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2010033074A1

  公开（公告）日：2010-03-25

  The invention relates to a novel method of treatment or prophylaxis of cancer, which comprises administering to a patient in need thereof a therapeutically effective amount of a TLR7 agonist of Formula (I), or a pharmaceutically acceptable salt thereof.

  该发明涉及一种治疗或预防癌症的新方法，包括向需要的患者施用公式（I）的TLR7激动剂或其药学上可接受的盐的治疗有效量。
• CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS
  申请人：CAYLA

  公开号：US20140141033A1

  公开（公告）日：2014-05-22

  A conjugated compound of formula Q-Z—R 4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R 4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

  一种配方为Q-Z—R4的共轭化合物，其中Q是TLR7和/或TLR8激动剂，Z—R4是TLR2激动剂，以及它们在治疗感染、癌症或免疫紊乱或用于疫苗中的用途。
• Novel adenne derivatives
  申请人：——

  公开号：US20040132748A1

  公开（公告）日：2004-07-08

  This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): 1 wherein X represents NR 3 (wherein R 3 represents a hydrogen atom or C 1-3 alkyl) or the like; R 1 represents substituted or unsubstituted alkyl or the like; R 2 represents hydroxyl or the like; and Y represents a substituted or unsubstituted aromatic hetero ring or the like. Also, the present invention relates to pharmaceuticals such as an interferon inducer, antiviral agent, anticancer agent, type 2 helper T cell selective immune response inhibitor, antiallergic agent, and immune response modulator comprising the above derivative as an active ingredient.

  本发明涉及一种由通式（I）表示的腺嘌呤衍生物、其互变异构体或其药学上可接受的盐，其中X代表NR3（其中R3代表氢原子或C1-3烷基）或类似物；R1代表取代或未取代的烷基或类似物；R2代表羟基或类似物；Y代表取代或未取代的芳香杂环或类似物。此外，本发明还涉及将上述衍生物作为活性成分的药物，例如干扰素诱导剂、抗病毒剂、抗癌剂、2型辅助T细胞选择性免疫反应抑制剂、抗过敏剂和免疫反应调节剂。
• Novel adenine compound and use thereof
  申请人：Isobe Yoshiaki

  公开号：US20060052403A1

  公开（公告）日：2006-03-09

  A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X 1 represents oxygen, sulfur, NR 1 (R 1 represents hydrogen or alkyl), or a single bond; Y 1 represents a single bond, alkylene, etc.; Y 2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q 1 and Q 2 represents —COOR 10 (wherein R 10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

  一种适用于局部给药的药物，作为抗过敏剂有效。该药物含有一种腺嘌呤化合物作为活性成分，该化合物由通式（1）表示：[其中环A表示6-10个成员、单环或双环、芳香烃或含有1-3个杂原子（选自0-2个氮原子、0或1个氧原子和0或1个硫原子）的5-10个成员、单环或双环、芳香杂环；n为0-2的整数；m为0-2的整数；R表示卤素、（未）取代的烷基等；X1表示氧、硫、NR1（R1表示氢或烷基）或单键；Y1表示单键、亚烷基等；Y2表示单键、亚烷基等；Z表示亚烷基；Q1和Q2中至少一个表示—COOR10（其中R10表示（未）取代的烷基等），等等]或该化合物的药学上可接受的盐。